These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 10357046)

  • 1. Dysthymia: clinical picture, extent of overlap with chronic fatigue syndrome, neuropharmacological considerations, and new therapeutic vistas.
    Brunello N; Akiskal H; Boyer P; Gessa GL; Howland RH; Langer SZ; Mendlewicz J; Paes de Souza M; Placidi GF; Racagni G; Wessely S
    J Affect Disord; 1999; 52(1-3):275-90. PubMed ID: 10357046
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacotherapy of dysthymic and chronic depressive disorders: overview with focus on moclobemide.
    Versiani M
    J Affect Disord; 1998 Dec; 51(3):323-32. PubMed ID: 10333986
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The long-term outcome of dysthymia in private practice: clinical features, temperament, and the art of management.
    Haykal RF; Akiskal HS
    J Clin Psychiatry; 1999 Aug; 60(8):508-18. PubMed ID: 10485632
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Benefits and risks of pharmacotherapy for dysthymia: a systematic appraisal of the evidence.
    De Lima MS; Hotopf M
    Drug Saf; 2003; 26(1):55-64. PubMed ID: 12495364
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Delineating psychopathologic clusters within dysthymia: a study of 512 out-patients without major depression.
    Serretti A; Jori MC; Casadei G; Ravizza L; Smeraldi E; Akiskal H
    J Affect Disord; 1999 Nov; 56(1):17-25. PubMed ID: 10626776
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dopaminergic deficit and the role of amisulpride in the treatment of mood disorders.
    Montgomery SA
    Int Clin Psychopharmacol; 2002 Dec; 17 Suppl 4():S9-15; discussion S16-7. PubMed ID: 12685917
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prescribing patterns of psychotropic medications and clinical features in patients with major depressive disorder with and without comorbid dysthymia in China.
    Feng Y; Sha S; Hu C; Wang G; Ungvari GS; Chiu HF; Ng CH; Si TM; Chen DF; Fang YR; Lu Z; Yang HC; Hu J; Chen ZY; Huang Y; Sun J; Wang XP; Li HC; Zhang JB; Xiang YT
    Asia Pac Psychiatry; 2017 Mar; 9(1):. PubMed ID: 27759189
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A comparison of drugs versus placebo for the treatment of dysthymia.
    Lima MS; Moncrieff J
    Cochrane Database Syst Rev; 2000; (2):CD001130. PubMed ID: 10796749
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Drugs versus placebo for dysthymia.
    Lima MS; Moncrieff J
    Cochrane Database Syst Rev; 2000; (4):CD001130. PubMed ID: 11034701
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The efficacy of drug treatments for dysthymia: a systematic review and meta-analysis.
    de Lima MS; Hotoph M; Wessely S
    Psychol Med; 1999 Nov; 29(6):1273-89. PubMed ID: 10616934
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Open-label evaluation of venlafaxine sustained release in outpatients with generalized anxiety disorder with comorbid major depression or dysthymia: effectiveness, tolerability and predictors of response.
    Perugi G; Frare F; Toni C; Ruffolo G; Torti C
    Neuropsychobiology; 2002; 46(3):145-9. PubMed ID: 12422062
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacotherapy of dysthymia: a review.
    Howland RH
    J Clin Psychopharmacol; 1991 Apr; 11(2):83-92. PubMed ID: 2056146
    [TBL] [Abstract][Full Text] [Related]  

  • 13. General health, health care utilization, and medical comorbidity in dysthymia.
    Howland RH
    Int J Psychiatry Med; 1993; 23(3):211-38. PubMed ID: 8270354
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Posttraumatic stress disorder (PTSD) as a consequence of the interaction between an individual genetic susceptibility, a traumatogenic event and a social context].
    Auxéméry Y
    Encephale; 2012 Oct; 38(5):373-80. PubMed ID: 23062450
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The undertreatment of dysthymia.
    Shelton RC; Davidson J; Yonkers KA; Koran L; Thase ME; Pearlstein T; Halbreich U
    J Clin Psychiatry; 1997 Feb; 58(2):59-65. PubMed ID: 9062374
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A pharmacotherapy algorithm for the treatment of dysthymia in Japan.
    Kitamura H; Yokoyama T; Someya T
    Psychiatry Clin Neurosci; 1999 Oct; 53 Suppl():S49-53. PubMed ID: 10560899
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recognition and treatment of dysthymia in elderly patients.
    Bellino S; Bogetto F; Vaschetto P; Ziero S; Ravizza L
    Drugs Aging; 2000 Feb; 16(2):107-21. PubMed ID: 10755327
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An update on the pharmacotherapeutic strategies for the treatment of dysthymic disorder: a systematic review.
    Quagliato LA; Primavera D; Fornaro M; Preti A; Carta MG; Nardi AE
    Expert Opin Pharmacother; 2023; 24(18):2035-2040. PubMed ID: 37787056
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antidepressant efficacy in the treatment of dysthymia.
    Invernizzi G; Mauri MC; Waintraub L
    Eur Neuropsychopharmacol; 1997 Oct; 7 Suppl 3():S329-36. PubMed ID: 9405959
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Second-generation antipsychotics for major depressive disorder and dysthymia.
    Komossa K; Depping AM; Gaudchau A; Kissling W; Leucht S
    Cochrane Database Syst Rev; 2010 Dec; (12):CD008121. PubMed ID: 21154393
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.